vs
德康医疗（DXCM）与思佳讯（SWKS）财务数据对比。点击上方公司名可切换其他公司
德康医疗的季度营收约是思佳讯的1.3倍（$1.3B vs $943.7M），德康医疗净利率更高（21.2% vs 3.8%，领先17.4%），德康医疗同比增速更快（21.6% vs -1.0%），过去两年德康医疗的营收复合增速更高（12.0% vs 2.1%）
德康医疗是美国跨国医疗保健企业，专注于研发、生产及销售糖尿病管理领域的连续血糖监测（CGM）系列系统。其全球总部及研发中心位于美国加利福尼亚州圣地亚哥，生产基地分布于美国亚利桑那州梅萨、马来西亚峇都交湾及爱尔兰戈尔韦郡阿斯里。
思佳讯是总部位于美国加利福尼亚州尔湾的半导体企业，公司股票在纳斯达克全球精选市场挂牌交易，股票代码为SWKS，同时也是标普500指数的成分股之一，在全球射频半导体领域拥有较高市场地位。
DXCM vs SWKS — 直观对比
营收规模更大
DXCM
是对方的1.3倍
$943.7M
营收增速更快
DXCM
高出22.6%
-1.0%
净利率更高
DXCM
高出17.4%
3.8%
两年增速更快
DXCM
近两年复合增速
2.1%
损益表 — Q1 FY2026 vs Q3 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $1.3B | $943.7M |
| 净利润 | $267.3M | $35.6M |
| 毛利率 | 62.9% | 40.8% |
| 营业利润率 | 25.6% | 4.5% |
| 净利率 | 21.2% | 3.8% |
| 营收同比 | 21.6% | -1.0% |
| 净利润同比 | 153.6% | -48.2% |
| 每股收益（稀释后） | $0.67 | $0.24 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收DXCMSWKS
| Q2 26 | — | $943.7M | ||
| Q1 26 | $1.3B | $1.0B | ||
| Q4 25 | $1.3B | $1.1B | ||
| Q3 25 | $1.2B | — | ||
| Q2 25 | $1.2B | $965.0M | ||
| Q1 25 | $1.0B | $953.2M | ||
| Q4 24 | $1.1B | $1.1B | ||
| Q3 24 | $994.2M | $1.0B |
净利润DXCMSWKS
| Q2 26 | — | $35.6M | ||
| Q1 26 | $267.3M | $79.2M | ||
| Q4 25 | $267.3M | $141.4M | ||
| Q3 25 | $283.8M | — | ||
| Q2 25 | $179.8M | $105.0M | ||
| Q1 25 | $105.4M | $68.7M | ||
| Q4 24 | $151.7M | $162.0M | ||
| Q3 24 | $134.6M | $60.5M |
毛利率DXCMSWKS
| Q2 26 | — | 40.8% | ||
| Q1 26 | 62.9% | 41.3% | ||
| Q4 25 | 62.9% | 40.7% | ||
| Q3 25 | 60.5% | — | ||
| Q2 25 | 59.5% | 41.6% | ||
| Q1 25 | 56.9% | 41.1% | ||
| Q4 24 | 58.9% | 41.4% | ||
| Q3 24 | 59.7% | 41.9% |
营业利润率DXCMSWKS
| Q2 26 | — | 4.5% | ||
| Q1 26 | 25.6% | 10.0% | ||
| Q4 25 | 25.6% | 10.1% | ||
| Q3 25 | 20.1% | — | ||
| Q2 25 | 18.4% | 11.5% | ||
| Q1 25 | 12.9% | 10.2% | ||
| Q4 24 | 17.0% | 16.9% | ||
| Q3 24 | 15.3% | 5.8% |
净利率DXCMSWKS
| Q2 26 | — | 3.8% | ||
| Q1 26 | 21.2% | 7.6% | ||
| Q4 25 | 21.2% | 12.9% | ||
| Q3 25 | 23.5% | — | ||
| Q2 25 | 15.5% | 10.9% | ||
| Q1 25 | 10.2% | 7.2% | ||
| Q4 24 | 13.6% | 15.2% | ||
| Q3 24 | 13.5% | 5.9% |
每股收益（稀释后）DXCMSWKS
| Q2 26 | — | $0.24 | ||
| Q1 26 | $0.67 | $0.53 | ||
| Q4 25 | $0.67 | $0.95 | ||
| Q3 25 | $0.70 | — | ||
| Q2 25 | $0.45 | $0.70 | ||
| Q1 25 | $0.27 | $0.43 | ||
| Q4 24 | $0.37 | $1.00 | ||
| Q3 24 | $0.34 | $0.36 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $917.7M | — |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $2.7B | $5.8B |
| 总资产 | $6.3B | $7.9B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资DXCMSWKS
| Q2 26 | — | — | ||
| Q1 26 | $917.7M | $1.6B | ||
| Q4 25 | $917.7M | $1.4B | ||
| Q3 25 | $1.8B | — | ||
| Q2 25 | $1.2B | $1.3B | ||
| Q1 25 | $904.9M | $1.5B | ||
| Q4 24 | $606.1M | $1.7B | ||
| Q3 24 | $621.2M | $1.6B |
总债务DXCMSWKS
| Q2 26 | — | — | ||
| Q1 26 | — | $496.6M | ||
| Q4 25 | — | $496.4M | ||
| Q3 25 | — | — | ||
| Q2 25 | — | $496.2M | ||
| Q1 25 | — | $995.1M | ||
| Q4 24 | — | $994.7M | ||
| Q3 24 | — | $994.3M |
股东权益DXCMSWKS
| Q2 26 | — | $5.8B | ||
| Q1 26 | $2.7B | $5.8B | ||
| Q4 25 | $2.7B | $5.8B | ||
| Q3 25 | $2.7B | — | ||
| Q2 25 | $2.6B | $5.7B | ||
| Q1 25 | $2.3B | $5.9B | ||
| Q4 24 | $2.1B | $6.4B | ||
| Q3 24 | $2.0B | $6.3B |
总资产DXCMSWKS
| Q2 26 | — | $7.9B | ||
| Q1 26 | $6.3B | $7.9B | ||
| Q4 25 | $6.3B | $7.9B | ||
| Q3 25 | $7.5B | — | ||
| Q2 25 | $7.3B | $7.7B | ||
| Q1 25 | $6.8B | $7.9B | ||
| Q4 24 | $6.5B | $8.3B | ||
| Q3 24 | $6.4B | $8.3B |
负债/权益比DXCMSWKS
| Q2 26 | — | — | ||
| Q1 26 | — | 0.09× | ||
| Q4 25 | — | 0.09× | ||
| Q3 25 | — | — | ||
| Q2 25 | — | 0.09× | ||
| Q1 25 | — | 0.17× | ||
| Q4 24 | — | 0.16× | ||
| Q3 24 | — | 0.16× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | — | $50.3M |
| 自由现金流经营现金流 - 资本支出 | — | — |
| 自由现金流率自由现金流/营收 | — | — |
| 资本支出强度资本支出/营收 | — | 8.7% |
| 现金转化率经营现金流/净利润 | — | 1.41× |
| 过去12个月自由现金流最近4个季度 | — | — |
8季度趋势，按日历期对齐
经营现金流DXCMSWKS
| Q2 26 | — | $50.3M | ||
| Q1 26 | — | $395.5M | ||
| Q4 25 | $294.0M | $200.0M | ||
| Q3 25 | $659.9M | — | ||
| Q2 25 | $303.0M | $314.2M | ||
| Q1 25 | $183.8M | $409.4M | ||
| Q4 24 | $301.4M | $377.2M | ||
| Q3 24 | $199.5M | $476.1M |
自由现金流DXCMSWKS
| Q2 26 | — | — | ||
| Q1 26 | — | $339.0M | ||
| Q4 25 | $192.1M | $144.0M | ||
| Q3 25 | $579.4M | — | ||
| Q2 25 | $208.9M | $252.7M | ||
| Q1 25 | $96.8M | $370.9M | ||
| Q4 24 | $176.8M | $338.2M | ||
| Q3 24 | $88.3M | $393.3M |
自由现金流率DXCMSWKS
| Q2 26 | — | — | ||
| Q1 26 | — | 32.7% | ||
| Q4 25 | 15.3% | 13.1% | ||
| Q3 25 | 47.9% | — | ||
| Q2 25 | 18.1% | 26.2% | ||
| Q1 25 | 9.3% | 38.9% | ||
| Q4 24 | 15.9% | 31.7% | ||
| Q3 24 | 8.9% | 38.4% |
资本支出强度DXCMSWKS
| Q2 26 | — | 8.7% | ||
| Q1 26 | — | 5.5% | ||
| Q4 25 | 8.1% | 5.1% | ||
| Q3 25 | 6.7% | — | ||
| Q2 25 | 8.1% | 6.4% | ||
| Q1 25 | 8.4% | 4.0% | ||
| Q4 24 | 11.2% | 3.6% | ||
| Q3 24 | 11.2% | 8.1% |
现金转化率DXCMSWKS
| Q2 26 | — | 1.41× | ||
| Q1 26 | — | 4.99× | ||
| Q4 25 | 1.10× | 1.41× | ||
| Q3 25 | 2.33× | — | ||
| Q2 25 | 1.69× | 2.99× | ||
| Q1 25 | 1.74× | 5.96× | ||
| Q4 24 | 1.99× | 2.33× | ||
| Q3 24 | 1.48× | 7.87× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
